thymidine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Yuan, M | 1 |
| Zhang, J | 1 |
| He, Y | 1 |
| Yi, G | 1 |
| Rong, L | 1 |
| Zheng, L | 1 |
| Zhan, T | 1 |
| Zhou, C | 1 |
| Sun, K | 1 |
| Xu, Y | 1 |
| Zhang, L | 1 |
| Niravath, P | 1 |
| Darcourt, J | 1 |
| Patel, T | 1 |
| Teh, BS | 1 |
| Farach, AM | 1 |
| Guerrero, C | 1 |
| Mathur, S | 1 |
| Sultenfuss, MA | 1 |
| Gupta, N | 1 |
| Schwartz, MR | 1 |
| Haley, SL | 1 |
| Nair, S | 1 |
| Li, X | 1 |
| Nguyen, TTA | 1 |
| Butner, JD | 1 |
| Ensor, J | 1 |
| Mejia, JA | 1 |
| Mei, Z | 1 |
| Butler, EB | 1 |
| Chen, SH | 1 |
| Bernicker, EH | 1 |
| Chang, JC | 1 |
| Raccagni, I | 1 |
| Belloli, S | 1 |
| Valtorta, S | 1 |
| Stefano, A | 1 |
| Presotto, L | 1 |
| Pascali, C | 1 |
| Bogni, A | 1 |
| Tortoreto, M | 1 |
| Zaffaroni, N | 1 |
| Daidone, MG | 1 |
| Russo, G | 1 |
| Bombardieri, E | 1 |
| Moresco, RM | 1 |
1 trial available for thymidine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Genetic Therapy; Humans; Immune Checkpoint Inhibitor | 2022 |
2 other studies available for thymidine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Circ_0062558 promotes growth, migration, and glutamine metabolism in triple-negative breast cancer by targeting the miR-876-3p/SLC1A5 axis.
Topics: Amino Acid Transport System ASC; Amino Acid Transport Systems, Neutral; Animals; Bromides; Cell Line | 2022 |
[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Cell Line, Tumor; Female; Fluorodeoxyg | 2018 |